TY - JOUR
T1 - Corrigendum to Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer (eBioMedicine (2018) 38 (100–112), (S2352396418304973), (10.1016/j.ebiom.2018.11.004))
AU - Kanlikilicer, Pinar
AU - Bayraktar, Recep
AU - Denizli, Merve
AU - Rashed, Mohammed H.
AU - Ivan, Cristina
AU - Aslan, Burcu
AU - Mitra, Rahul
AU - Karagoz, Kubra
AU - Bayraktar, Emine
AU - Zhang, Xinna
AU - Rodriguez-Aguayo, Cristian
AU - El-Arabey, Amr Ahmed
AU - Kahraman, Nermin
AU - Baydogan, Seyda
AU - Ozkayar, Ozgur
AU - Gatza, Michael L.
AU - Ozpolat, Bulent
AU - Calin, George A.
AU - Sood, Anil K.
AU - Lopez-Berestein, Gabriel
N1 - Publisher Copyright:
© 2024 The Author(s)
PY - 2025/1
Y1 - 2025/1
N2 - In our recent publication titled “Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer” published in Ebiomedicine, Volume 38, Page 100–112, Dec 2018, an error in Figure 3e with beta-actin bands was identified. The unintentional error occurred due to an orientation issue with the film development of the beta-actin bands. Specifically, during the detection of Western blot beta-actin signal, first exposure of the membrane gave us strong signals with overexposed bands. We used the bottom part of the same X-ray film for the development of second exposure without being in contact with one another. Second exposure was taken up-side down orientation on the same X-ray film ensuring there is no contact with the first exposed view of the beta-actin bands. However, opposite orientation of the bands on the second exposure led to misinterpretation of the bands and beta-actin bands for Figure 3e were not taken appropriately for the samples labeled. We apologize for any confusion or inconvenience this may have caused. We have since re-evaluated the results using the original uncropped X-ray images, and corrected the figure, containing the appropriate beta-actin bands from the first exposure, is provided below.[Formula presented] We are committed to upholding the highest standards of scientific accuracy and transparency, and we have implemented additional checks in our processes to prevent similar errors in future work. We sincerely apologize for any inconvenience this error may have caused and appreciate the understanding and continued support of the scientific community.
AB - In our recent publication titled “Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer” published in Ebiomedicine, Volume 38, Page 100–112, Dec 2018, an error in Figure 3e with beta-actin bands was identified. The unintentional error occurred due to an orientation issue with the film development of the beta-actin bands. Specifically, during the detection of Western blot beta-actin signal, first exposure of the membrane gave us strong signals with overexposed bands. We used the bottom part of the same X-ray film for the development of second exposure without being in contact with one another. Second exposure was taken up-side down orientation on the same X-ray film ensuring there is no contact with the first exposed view of the beta-actin bands. However, opposite orientation of the bands on the second exposure led to misinterpretation of the bands and beta-actin bands for Figure 3e were not taken appropriately for the samples labeled. We apologize for any confusion or inconvenience this may have caused. We have since re-evaluated the results using the original uncropped X-ray images, and corrected the figure, containing the appropriate beta-actin bands from the first exposure, is provided below.[Formula presented] We are committed to upholding the highest standards of scientific accuracy and transparency, and we have implemented additional checks in our processes to prevent similar errors in future work. We sincerely apologize for any inconvenience this error may have caused and appreciate the understanding and continued support of the scientific community.
UR - http://www.scopus.com/inward/record.url?scp=85210625703&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85210625703&partnerID=8YFLogxK
U2 - 10.1016/j.ebiom.2024.105486
DO - 10.1016/j.ebiom.2024.105486
M3 - Comment/debate
C2 - 39637523
AN - SCOPUS:85210625703
SN - 2352-3964
VL - 111
JO - EBioMedicine
JF - EBioMedicine
M1 - 105486
ER -